Combination DMARD therapy with hydroxychloroquine, sulfasalazine, and methotrexate.
نویسنده
چکیده
Triple combination therapy with hydroxychloroquine, sulfasalazine, and methotrexate (MTX) has been shown in double-blind, placebo-controlled studies to be significantly superior to MTX alone (Paulus 50% responses of 77% versus 33%). In long-term follow-up studies, this therapy has now been shown to be well-tolerated with continued efficacy in the majority of patients.
منابع مشابه
Combination disease-modifying antirheumatic drug therapy reduced work disability in early rheumatoid arthritis.
M e t h o d s Design: Randomized controlled trial (Finnish Rheumatoid Arthritis Combination Therapy trial). Allocation: {Concealed}†.* Blinding: Blinded {outcome assessors}†.* Follow-up period: 5 years. Setting: 18 hospitals in Finland. Patients: 162 patients 18 to 65 years of age (mean age 45.5 y, 62% women) with RA of recent onset (< 2 y) and presence of active disease who had never received ...
متن کاملUse of combination therapy in the routine care of patients with rheumatoid arthritis: physician and patient surveys.
AIMS To describe the utilization of combination therapy in the treatment of rheumatoid arthritis (RA). METHODS Review of published articles and abstracts, and patient/physician questionnaire data. RESULTS Combination therapy was rarely used in the early 1980s and is now (1999) used for about 25% of RA patients in the US. Physician and patient surveys indicate that methotrexate plus hydroxyc...
متن کاملTwo-Year Safety and Efficacy Experience in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis Treated with Etanercept and Conventional Disease-Modifying Anti-rheumatic Drugs in the Latin American Region
BACKGROUND Although long-term data are available from biologic studies in North American/European populations with rheumatoid arthritis (RA), long-term findings in Latin American RA populations are limited. OBJECTIVE To examine long-term safety/efficacy of etanercept, methotrexate, and/or other disease-modifying anti-rheumatic drugs (DMARDs) in Latin American patients with moderate-to-severe ...
متن کاملCombination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis.
OBJECTIVE The response to single disease modifying antirheumatic drug (DMARD) is often suboptimal in patients with rheumatoid arthritis (RA). Thus, despite the limited data on the therapeutic efficacy of combination therapies, many patients are currently treated with a combination of DMARDs. METHODS We studied prospectively the efficacy of combination therapy with DMARDs. The study was design...
متن کاملRetardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study.
OBJECTIVE To evaluate the long-term frequency of disease remissions and the progression of joint damage in patients with early rheumatoid arthritis (RA) who were initially randomized to 2 years of treatment with either a combination of 3 disease-modifying antirheumatic drugs (DMARDs) or a single DMARD. METHODS In this multicenter prospective followup study, a cohort of 195 patients with early...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Clinical and experimental rheumatology
دوره 17 6 Suppl 18 شماره
صفحات -
تاریخ انتشار 1999